About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This BlogEye on FDA is published by Mark Senak of FleishmanHillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Monthly Archives: May 2011
The last Weekly Roundup of May! The first BBQ has happened. And sitting on my back deck, the sweet smell of honeysuckle wafts over from the fence. Petunias are in full riot. The basil is standing proudly and already being … Continue reading
A bunch of things are converging this week in my head. Here goes. On October 15, 1985 I was a guest on The Oprah Winfrey Show. It was in Chicago then, just before she went national. Just before. I had … Continue reading
This is about food, but also about medicine. This week the markup of the House Appropriations Agriculture Subcommittee was posted to the Committee’s Website revealing that the FDA was getting a $285 million dollar cut from last year’s budget and … Continue reading